Jefferies Financial Group’s C4 Therapeutics CCCC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$33.6K Buy
+10,080
New +$37.6K ﹤0.01% 1235
2026
Q2
– Sell
-26,120
Closed -$68.7K – 1699
2026
Q1
$68.7K Sell
26,120
-9,220
-26% -$21.7K ﹤0.01% 1630
2025
Q4
$67.5K Sell
35,340
-2,860
-7% -$6.78K ﹤0.01% 1744
2025
Q3
$84.8K Buy
+38,200
New +$91.7K ﹤0.01% 1356

Other funds holding CCCC

Jefferies Financial Group's CCCC Position: Q3 2026 in Review

Jefferies Financial Group opened a new position in C4 Therapeutics (CCCC) in Q3 2026: 10,080 shares worth $33.6K. The stake represents ﹤0.01% of the portfolio and ranks #1235 among its holdings. This is a return to the name: Jefferies Financial Group previously reported a position in CCCC as recently as Q1 2026.

Jefferies Financial Group first reported a position in CCCC in Q3 2025 and has held it in 4 quarters since. The position peaked at $84.8K in Q3 2025. 151 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

  • Jefferies Financial Group held 10,080 shares of C4 Therapeutics worth $33.6K as of Q3 2026.
  • C4 Therapeutics was a new Jefferies Financial Group position in Q3 2026.
  • C4 Therapeutics made up ﹤0.01% of Jefferies Financial Group's portfolio in Q3 2026, its #1235 holding.
  • Jefferies Financial Group first reported a position in C4 Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Jefferies Financial Group's C4 Therapeutics position peaked at $84.8K in Q3 2025.
  • 151 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on Jefferies Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.